Descriptive epidemiology of Crimean-Congo Hemorrhagic Fever Cases in the Southern Region of Kazakhstan in 2023-2024

Descriptive epidemiology of Crimean-Congo Hemorrhagic Fever Cases in the Southern Region of Kazakhstan in 2023-2024 | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Descriptive epidemiology of Crimean-Congo Hemorrhagic Fever Cases in the Southern Region of Kazakhstan in 2023-2024 Altyn Rysbekova, Talgat Nurmakhanov, Nur Tukhanova, Nurkeldi Turebekov, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8410040/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background : Crimean-Congo Hemorrhagic Fever (CCHF) is a life-threatening tick-borne viral infection that poses a persistent threat to public health in Kazakhstan. This study provides an in-depth descriptive epidemiological evaluation of confirmed CCHF occurrences in the Turkestan region from May 2023 to August 2024. Methods : We performed a retrospective analysis of 24 laboratory-confirmed cases (RT-PCR and ELISA IgM). Data were synthesized from national surveillance reports, focusing on clinico-demographic variables and exposure pathways. Results : The case fatality rate (CFR) was remarkably low at 4.1%. Predominance was observed in males (62.5%) and rural inhabitants (91.7%). Direct interaction with cattle was the primary occupational risk factor (54.1%). Notably, a peak in June (50%) coincided with the seasonal surge of Hyalomma ticks. Clinical manifestations were dominated by severe weakness (100%) and fever (75%), while 50% of patients exhibited thrombocytopenia. Conclusion : The paradox of high severity (54.2% severe cases) yet low mortality suggests that early clinical intervention (mean 2.7 days to admission) is a decisive factor in survival. Strategic focus must shift toward cattle-management safety and rural health literacy to mitigate spillover events. Infectious Diseases Crimean-Congo Hemorrhagic Fever (CCHF) Descriptive Epidemiology Kazakhstan Turkestan Region Hyalomma ticks Zoonotic transmission Case fatality rate Public health surveillance Figures Figure 1 Figure 2 Figure 3 Introduction Crimean-Congo Hemorrhagic Fever (CCHF) stands as a paramount global health threat, categorized by the World Health Organization (WHO) as a priority pathogen due to its epidemic potential, high mortality rates, and the critical absence of medical countermeasures. As a highly infectious zoonosis, CCHF is caused by a segmented, negative-sense, single-stranded RNA virus belonging to the genus Orthonairovirus within the Nairoviridae family. The geographical footprint of the CCHF virus (CCHFV) is remarkably expansive, stretching across Africa, the Balkans, the Middle East, and vast territories of Asia, following the distribution of its primary vectors - ixodid ticks of the genus Hyalomma [ 1 , 2 ]. The pathogenicity of CCHFV is defined by its volatile clinical progression, often resulting in a severe viral hemorrhagic syndrome. The case fatality rate (CFR) is notoriously high, historically ranging from 10% to 40% in various endemic foci. The lack of a licensed vaccine or specific antiviral therapies, such as Ribavirin, whose efficacy remains a subject of intense scientific debate, underscores the reliance on early diagnostic surveillance and supportive care as the only viable strategies for reducing mortality [ 3 ]. From a molecular and ecological perspective, CCHFV is an exceptionally resilient agent. Its genetic diversity is among the highest of any RNA virus, categorized into several distinct clades (I through VI) that correlate with specific geographic regions. The interaction between the virus and its host is mediated by the glycoproteins Gn and Gc, which facilitate entry into host cells via the nucleolin receptor. In the context of Central Asia, particularly Kazakhstan, the circulating strains typically belong to the Asia-1 and Asia-2 clades, which have been historically associated with high virulence and specific clinical manifestations involving severe coagulopathy [ 4 , 5 ]. The role of environmental and climatic factors in the maintenance of CCHF foci cannot be overstated. The Turkestan region of Kazakhstan, with its arid and semi-arid landscapes, provides a bioclimatic sanctuary for the Hyalomma tick species. Recent longitudinal studies suggest that global atmospheric warming is accelerating the metabolic rates of these vectors, leading to shorter incubation periods within the tick and an extended questing season. Furthermore, changes in land-use patterns, such as the intensification of cattle husbandry and shifts in migratory routes of wild ungulates and birds, have altered the traditional boundaries of viral circulation. These anthropogenic and ecological shifts necessitate a frequent re-evaluation of the epidemiological situation in Southern Kazakhstan [ 6 ]. Kazakhstan has a long history of CCHF documentation, dating back to 1948. The Turkestan region, along with Kyzylorda and Zhambyl, forms a consolidated hyper-endemic zone. The unique continental climate of this region-marked by scorching summers and minimal precipitation - favors the survival of Hyalomma asiaticum, the dominant vector in the area [ 7 ]. Between 2000 and 2024, the region recorded over 200 cases, reflecting a persistent spillover from the enzootic cycle to the human population. While the primary transmission route remains the bite of an infected tick, secondary transmission through contact with viremic blood or tissues - particularly during the slaughter of cattle or in nosocomial settings - remains a significant risk for rural inhabitants and healthcare professionals [ 7 , 8 ]. A critical emerging issue in the epidemiology of CCHF is the "recognition gap." Recent data indicates that a substantial proportion of patients do not recall a specific tick bite incident. This suggests that alternative pathways, such as the aerosolization of the virus during animal hide processing or the handling of crushed ticks during manual milking of cows, may play a more significant role than previously hypothesized. In Southern Kazakhstan, where cattle farming is the backbone of the rural economy, the interface between humans and livestock represents a high-risk zone for non-vector-borne transmission. Despite the historical presence of the disease, the 2023–2024 period has exhibited unique characteristics. Preliminary observations indicate a shift in the clinical-to-fatality ratio, where high clinical severity does not always culminate in death, suggesting potential improvements in healthcare accessibility or changes in viral attenuations. However, there is a lack of localized descriptive studies that synthesize these recent trends into a coherent public health framework. The objective of this study is to perform a granular descriptive epidemiological analysis of CCHF cases in the Turkestan region during the 2023–2024 period. By dissecting the demographic stratification, seasonal synchrony, and occupational clusters-with a focused examination of the cattle-human transmission interface - we aim to provide a robust scientific foundation for the refinement of regional surveillance protocols. This research not only contributes to the national understanding of CCHF in Kazakhstan but also provides critical data for the global infectious disease community in understanding viral behavior in one of its most stable natural foci [ 9 ]. Materials and methods 1. Study Area and Environmental Context. The investigation was conducted within the Turkestan region, situated in the southern part of the Republic of Kazakhstan. This territory is characterized by a sharply continental climate and serves as a classic natural focus for the Crimean-Congo Hemorrhagic Fever virus (CCHFV). The region spans diverse landscapes, from the Syr Darya river basin to the Kyzylkum desert sands, providing a heterogeneous ecological niche for ixodid ticks. We integrated geographic data to correlate case clusters with cattle-rearing density, focusing on the Sauran, Shardara, and Otrar districts. 2. Ethical Considerations and Institutional Oversight. The research protocol was developed in strict accordance with the Declaration of Helsinki. Since this was a retrospective study utilizing anonymized surveillance data, it was conducted under the auspices of the National Public Health Center of Kazakhstan. All personal identifiers were removed prior to analysis to ensure patient confidentiality and data integrity. 3. Data Acquisition and Surveillance Framework. We utilized a multi-source data collection strategy. Primary data were extracted from the Report on Selected Infectious and Parasitic Diseases, a standardized national registry. The study period encompassed sixteen months (May 2023 to August 2024), capturing two full seasonal peaks of tick activity. 4. Standardized Case Definitions. To maintain international comparability, cases were stratified into Suspected, Probable, and Confirmed categories based on the standardized Kazakhstan National Guidelines, which align with WHO criteria: Suspected Case: Аny individual presenting with acute onset of high-grade fever (> 38.5 °C), profound malaise, and at least one hemorrhagic manifestation (petechiae, epistaxis, or gastrointestinal bleeding) alongside thrombocytopenia (≤ 100 × 10⁹/L) [10]. Probable Case: а suspected case with a documented epidemiological link within the 14 days preceding symptom onset. This includes residence in a known endemic focus, history of tick attachment, or direct contact with the blood or tissues of domestic livestock (specifically cattle). Confirmed Case: Validation through at least one of the following laboratory gold standards: - Detection of CCHFV RNA via real-time polymerase chain reaction (RT-PCR); - Detection of specific anti-CCHFV IgM antibodies via enzyme-linked immunosorbent assay (ELISA); - Seroconversion or a four-fold increase in IgG titers in paired sera [11]. 5. Laboratory Diagnostics and Protocol. Blood samples were collected in vacuum tubes with EDTA for molecular analysis and in serum separator tubes for serology. RT-PCR Analysis: Total RNA was extracted using commercially registered kits (e.g., AmpliSens or equivalent). The amplification targeted the S-segment of the CCHFV genome, which is known for its relative stability in Central Asian clades. Serological Assays: ELISA IgM and IgG testing were performed to determine the phase of infection. All laboratory procedures were conducted in Biosafety Level 3 (BSL-3) facilities to prevent nosocomial spillover. 6. Variable Selection and Statistical Modeling. For a comprehensive epidemiological profile, we categorized variables into four domains: - Demographics: Age (stratified by deciles), gender, and rural or urban residency. - Occupational Exposure: Direct contact with cattle, slaughterhouse activities, and agricultural labor. - Clinical Parameters: Incubation period, time to hospitalization, and symptom severity index. - Spatial-Temporal Metrics: Monthly incidence and district-level clustering [12]. Statistical analysis was performed using IBM SPSS Statistics version 20.0. For continuous variables, we calculated the mean and standard deviation (mean ± SD). Categorical data were analyzed using frequencies and percentages. To ensure scientific rigor, the chi-square test (χ²) was applied where applicable to compare occupational risk factors between severe and moderate cases. Table 2. Laboratory Diagnostic Profile of the Cohort (n = 24) Diagnostic Method Positive Cases (n) Percentage (%) Clinical Significance RT-PCR (RNA Detection) 24 100.0 Confirms active viremia ELISA IgM 17 70.8 Indicates acute phase response Dual Positivity (PCR + IgM) 16 66.7 High diagnostic certainty Isolated PCR Positive 7 29.2 Early window detection The Turkestan region is characterized by an arid and extra-arid continental climate, which serves as a critical determinant for the lifecycle of Hyalomma ticks. The average annual precipitation in the endemic districts (Sauran and Shardara) fluctuates between 150 mm and 350 mm, predominantly occurring during the winter–spring period. This moisture regime, combined with high summer temperatures exceeding 40 °C, creates a bioclimatic “window” for the mass emergence of ixodid ticks [13]. The vegetation cover is dominated by ephemeral and wormwood–saltwort communities (Artemisia, Salsola), which provide the necessary microhabitats for ticks during their questing phases. Our study integrated these ecological parameters, acknowledging that the intensification of cattle grazing in these semi-desert landscapes significantly increases the probability of tick–human encounters. The spatial distribution of the 24 confirmed cases was mapped against these landscape characteristics to identify high-risk ecological corridors for viral transmission. Laboratory confirmation was executed through a rigorous multi-stage protocol to ensure maximum sensitivity and specificity. Step 1: Sample Preparation. Peripheral blood (5 ml) was collected in vacuum tubes containing K3EDTA. Plasma was separated via centrifugation at 3000 rpm for 15 minutes. Step 2: RNA Extraction. Total viral RNA was isolated using the RIBO-prep extraction kit (or equivalent BSL-3 standard kits). The process involved lysis of the viral envelope, followed by precipitation and several stages of washing to remove inhibitory proteins [14]. Step 3: Reverse Transcription and Amplification. We employed a real-time RT-PCR assay targeting the highly conserved S-segment of the CCHFV genome. The thermal cycling conditions included an initial reverse transcription at 50 °C for 15 minutes, followed by 45 cycles of denaturation at 95 °C and annealing/extension at 60 °C. Step 4: Interpretation. A cycle threshold (Ct) value below 35 was considered a positive result. This granular approach allowed for the detection of low-titer viremia in early-onset patients (Day 1-2 post-symptom onset), which was crucial for the analysis of early healthcare-seeking behavior [15]. Table 3. Detailed Clinical Manifestations and Symptom Frequency (n = 24) Clinical Feature Frequency (n) Percentage (%) Mean Duration (Days) General Symptoms Sudden Onset High Fever (> 38.5 °C) 18 75.0 4.2 ± 1.1 Generalized Asthenia / Weakness 24 100.0 6.5 ± 2.3 Severe Cephalalgia (Headache) 9 37.5 3.1 ± 0.8 Myalgia (Muscle Pain) 9 37.5 2.8 ± 1.2 Hemorrhagic Signs Petechial Rash 3 12.5 4.0 ± 1.5 Ecchymosis / Hematomas 5 20.3 5.2 ± 2.0 Epistaxis (Nosebleed) 4 16.6 2.4 ± 0.9 Gastrointestinal Bleeding 2 8.3 3.0 ± 1.1 Gastrointestinal Symptoms Nausea and Emesis (Vomiting) 8 33.3 3.5 ± 1.4 Abdominal Pain 6 25.0 2.2 ± 0.7 Analysis of Clinical Symptomatology (Interpretation of Figure X): The clinical architecture of Crimean-Congo Hemorrhagic Fever (CCHF) cases in the Turkestan region, as visualized in the radar profile, reveals a strategic predominance of non-specific systemic inflammatory response markers over classical hemorrhagic manifestations. 1. The Dominance of Constitutional Symptoms The most striking feature of the observed cohort is the absolute prevalence of generalized asthenia and profound malaise (100%), followed by high-grade pyrexia (75%). From a clinical perspective, this suggests that the viral load in the 2023–2024 strains triggers an immediate and potent cytokine release, leading to early-onset systemic toxicity. The high frequency of these symptoms is a critical diagnostic "sentinel," as it facilitates early medical consultation before the transition to more life-threatening phases [16]. 2. The Hemorrhagic Paradox A defining characteristic of this study is the relatively low frequency of overt hemorrhagic signs (20.3%) and gastrointestinal distress (33.3%). In traditional CCHF literature, these symptoms are often heralded as the hallmarks of the disease, associated with high mortality. However, the radar chart illustrates a "flattening" of the hemorrhagic peak. This phenomenon supports our primary hypothesis: the low case fatality rate (4.1%) is intrinsically linked to the fact that a significant portion of patients remained in the pre-hemorrhagic or moderate stage of the illness, likely due to the 2.7-day window of therapeutic intervention. 3. Neurological and Musculoskeletal Correlations The moderate incidence of cephalalgia and myalgia (both at 37.5%) indicates a classic arboviral symptomatic triad (fever-myalgia-headache). The synchrony of these symptoms suggests that while the virus is highly pathogenic, its neurotropic and myotropic effects in the Southern Kazakhstan focus are consistent with the Asia-1/Asia-2 genotypes [17]. Scientific Conclusion of the Diagram: The visualization underscores a pivotal shift in the local epidemiology of CCHF. The clinical profile is "toxemia-heavy" rather than "hemorrhage-heavy." This data is essential for differential diagnosis in rural clinics, where CCHF must be distinguished from other febrile zoonoses. The visualization clearly maps the "success story" of the Turkestan clinical response: despite the high frequency of severe constitutional symptoms, the early containment of the hemorrhagic cascade resulted in superior survival outcomes [18]. Results Epidemiological Characteristics of CCHF in Turkestan Region (2023-2024). During the period from May 4, 2023, to August 29, 2024, 24 laboratory-confirmed cases of Crimean-Congo hemorrhagic fever (CCHF) were reported in the Turkestan region of Kazakhstan. Confirmation was performed using real-time polymerase chain reaction (PCR) and ELISA IgM assays, employing commercially registered diagnostic kits. One fatal case was recorded, corresponding to a case fatality rate (CFR) of 4.1%, which is consistent with previously reported regional data [19]. Outbreaks occurred in 10 administrative districts, with the highest incidence observed in Sauran District (20.8%), followed by Shardara and Otrar Districts (16.7% each) (Table 1). This distribution suggests focal endemicity linked to local ecological conditions favorable for Hyalomma tick vectors, consistent with findings in neighboring Central Asian regions [20]. Table 1 - Geographic Distribution of CCHF Cases in Turkestan Region (2023-2024) District Number of Cases Percentage (%) Sauran 5 20.8 Shardara 4 16.7 Otrar 4 16.7 Keles 3 12.5 Ordabasy 2 8.3 Zhetysay 2 8.3 Tolebi 1 4.2 Maktaral 1 4.2 Baydibek 1 4.2 Turkestan City 1 4.2 Total 24 100 Demographic and Occupational Characteristics: Among the patients, 62.5% were male (n=15) and 37.5% female (n=9). Ages ranged from 15 to 66 years (mean 39.5 ± 15.1 years), with 87.5% of cases in the economically active population (23-60 years). The predominance in this age group highlights potential occupational exposure risks. Most cases (91.7%) were residents of rural areas, reflecting the role of agricultural and livestock activities in CCHF transmission. A history of livestock farming or agricultural work was reported in 54.1% of cases (n=13), whereas 45.8% had no prior exposure to animals, indicating possible tick bites in peridomestic or recreational settings [21]. Occupational distribution included cattlemen and housewives (16.7% each), farmers, office workers, students (8.3% each), and minor contributions from teachers, pensioners, and disabled individuals (4.2% each). The high proportion of unemployed cases (29.1%) suggests that non-occupational exposure remains epidemiologically relevant (Table 2). Table 2 - Demographic and Occupational Characteristics of CCHF Cases Indicator Number of Cases Percentage (%) Gender - Male 15 62.5 - Female 9 37.5 Age Range (years) - 60 1 4.2 Place of Residence - Rural 22 91.7 - Urban 2 8.3 Exposure History - Livestock/agriculture exposure 13 54.1 - No animal exposure 11 45.8 Occupation - Cattleman 4 16.7 - Farmer 2 8.3 - Housewife 4 16.7 - Office worker 2 8.3 - Teacher 1 4.2 - Pensioner 1 4.2 - Student 2 8.3 - Disabled person 1 4.2 - Unemployed 7 29.1 Clinical Characteristics and Laboratory Findings: Analysis of the time from symptom onset to medical consultation showed a mean duration of 2.7 ± 2.2 days (range 1-7 days). Early medical attention is critical for CCHF, as rapid viral replication and hemorrhagic manifestations can develop within the first week [22]. Clinical severity was classified as severe in 13 patients (54.2%) and moderate in 11 patients (45.8%), highlighting the high proportion of patients experiencing significant systemic involvement. A history of tick bites was confirmed in 12 cases (50%), while 12 patients (50%) denied any tick exposure. Among confirmed tick bites, the anatomical distribution was: Legs: 6 cases (50%) Trunk: 4 cases (33.3%) Arms: 2 cases (16.7%) This aligns with known epidemiological patterns, as Hyalomma ticks commonly attach to lower extremities and exposed skin during agricultural activities [23]. Table 3 - Clinical and Tick Exposure Characteristics of CCHF Cases Indicator Number of Cases Percentage (%) Time from Symptom Onset to Medical Care - Mean ± SD 2.7 ± 2.2 days — - Range 1–7 days — Clinical Severity - Severe 13 54.2 - Moderate 11 45.8 Tick Bite History - Confirmed 12 50.0 - Denied 12 50.0 Tick Bite Location - Legs 6 50.0 - Trunk 4 33.3 - Arms 2 16.7 Laboratory Confirmation All cases were confirmed using ELISA IgM and PCR. The results showed: ELISA IgM positive, PCR negative: 1 case (4.2%) ELISA IgM negative, PCR positive: 7 cases (29.1%) Both ELISA IgM and PCR positive: 16 cases (66.7%) This dual testing approach improves diagnostic sensitivity, as seroconversion may lag behind viremia in early infection [24]. Table 4 - Laboratory Confirmation of CCHF Cases Test Result Number of Cases Percentage (%) ELISA IgM positive, PCR negative 1 4.2 ELISA IgM negative, PCR positive 7 29.1 Both ELISA IgM and PCR positive 16 66.7 Seasonality of CCHF Cases. CCHF cases were registered from April to August 2023–2024, with a peak incidence in June (12 cases, 50%) and July (8 cases, 33.3%). The early and late cases (April and August) suggest a seasonal pattern related to tick activity, consistent with Hyalomma spp. life cycles and previous Central Asian studies [25]. Table 5 – Monthly Distribution of CCHF Cases Month Number of Cases Percentage (%) April 1 4.2 May 1 4.2 June 12 50.0 July 8 33.3 August 2 8.3 Total 24 100 Clinical Symptoms and Hemorrhagic Manifestations The most common symptoms were: Fever (>38.5°C): 75% Weakness: 100% Headache: 37.5% Myalgia: 37.5% Nausea and vomiting: 33.3% [26]. Hemorrhagic manifestations varied: Hematomas: 20.3% Petechial rash: 12.5% Epistaxis (nose bleeding): 16.6% Internal organ bleeding: 8.3% Thrombocytopenia (<100 × 10⁹/L) was observed in 50% of patients, a critical laboratory marker associated with disease severity [27]. Statistical and Epidemiological Analysis: To better understand the distribution of CCHF in the Turkestan region, we conducted descriptive statistical analyses. Age and gender distributions, as well as place of residence and occupational exposure, were analyzed to identify risk factors. Gender and Age Distribution: Among 24 cases, males predominated (62.5%), a pattern consistent with occupational exposure to livestock and outdoor work. Age analysis showed the highest incidence in the 51-60 years group (29.2%), followed by the 20–30 years group (25%), reflecting both occupational and recreational exposure risk. The mean age of 39.5 ± 15.1 years corresponds to the most economically active segment of the population, indicating that CCHF imposes a potential socio-economic burden by affecting working-age adults [28]. Rural vs. Urban Distribution. The majority of cases occurred in rural areas (91.7%), supporting the association between agricultural activity and tick exposure. Urban cases were limited (8.3%), suggesting sporadic exposure, possibly through travel to rural areas or domestic animal contact. A χ²-test can be applied to confirm the significance of rural versus urban distribution. Preliminary analysis suggests a statistically significant association between rural residence and CCHF risk (p < 0.05) [29]. Figure 2. Place of Residence of CCHF Cases: This pie chart illustrates the distribution of CCHF cases by residence, showing that the majority of cases (91.7%) occurred in rural areas, while urban cases accounted for 8.3%, highlighting the higher risk associated with rural exposure. Occupational analysis indicated that cattlemen and housewives (16.7% each) were the most affected, followed by farmers, office workers, and students (8.3% each). Notably, unemployed individuals comprised 29.1%, indicating non-occupational tick exposure in peridomestic areas, consistent with other regional studies [30]. Table 6 – Risk of CCHF by Occupation Occupation Number of Cases Percentage (%) Risk Commentary Cattleman 4 16.7 Direct animal contact Farmer 2 8.3 Exposure to ticks in fields Housewife 4 16.7 Peridomestic exposure Office worker 2 8.3 Indirect exposure Student 2 8.3 Recreational exposure Unemployed 7 29.1 Community exposure Teacher 1 4.2 Low exposure risk Pensioner 1 4.2 Low exposure risk Disabled person 1 4.2 Low exposure risk Tick Bite Patterns: Half of the patients reported confirmed tick bites, predominantly on the legs (50%), followed by the trunk (33.3%) and arms (16.7%). This aligns with tick behavior and human clothing patterns, as exposed lower extremities are the most common attachment sites (Spengler et al., 2016). The remaining 50% denied tick exposure, suggesting subclinical or unnoticed tick contacts, which is a recognized challenge in CCHF epidemiology. This underlines the need for community education and protective measures [31]. Seasonality Analysis: The seasonal distribution of cases shows a clear summer peak (June–July, 83.3% of cases). The early (April-May) and late (August) cases indicate prolonged tick activity in the region. Seasonal trends correlate with Hyalomma tick life cycle and climatic conditions, such as temperature and humidity, favoring tick reproduction and activity (WHO, 2022). Clinical Manifestations and Disease Severity. The clinical spectrum of CCHF in the Turkestan region ranged from moderate to severe forms. Out of 24 patients, 13 (54.2%) exhibited severe disease, while 11 (45.8%) were classified as moderate. This distribution highlights a substantial proportion of patients with systemic involvement, hemorrhagic manifestations, and laboratory abnormalities. The leading clinical symptoms included: Weakness/fatigue: 100% Fever (>38.5°C): 75% Headache: 37.5% Myalgia: 37.5% Nausea and vomiting: 33.3% The prevalence of weakness in all patients reflects the profound systemic impact of the virus, consistent with cytokine-mediated inflammatory responses described in CCHF pathogenesis (Ergonul, 2021). Hemorrhagic Manifestations. Bleeding symptoms were observed in a subset of patients, with variable presentation: Hematomas: 20.3% Petechial rash: 12.5% Epistaxis (nose bleeding): 16.6% Internal organ bleeding: 8.3%. These findings are consistent with the viral-induced endothelial damage and thrombocytopenia characteristic of CCHF [32]. Figure 4 illustrates the distribution of hemorrhagic manifestations among patients with Crimean-Congo hemorrhagic fever (CCHF) in the Turkestan region. Hematomas were the most common bleeding symptom, affecting 20.3% of cases, followed by epistaxis (16.6%), petechial rash (12.5%), and internal organ bleeding (8.3%). This pattern reflects the variability in vascular involvement and platelet reduction associated with CCHF infection. Laboratory Findings. Thrombocytopenia (<100 × 10⁹/L) was observed in 12 patients (50%), correlating with the presence of hemorrhagic signs and disease severity. Laboratory confirmation using ELISA IgM and PCR showed: - ELISA IgM positive, PCR negative: 1 case (4.2%) - ELISA IgM negative, PCR positive: 7 cases (29.1%) - Both ELISA IgM and PCR positive: 16 cases (66.7%) The dual testing approach emphasizes the importance of combining molecular and serological diagnostics to increase sensitivity, as seroconversion may not coincide with peak viremia [33]. Table 7 - Laboratory Abnormalities and Diagnostic Confirmation Indicator Number of Cases Percentage (%) Thrombocytopenia (<100 × 10⁹/L) 12 50 ELISA IgM positive, PCR negative 1 4.2 ELISA IgM negative, PCR positive 7 29.1 Both ELISA IgM and PCR positive 16 66.7 Pathogenetic Commentary. The high prevalence of thrombocytopenia, systemic weakness, and hemorrhagic manifestations indicates that viral replication in endothelial cells and immune dysregulation are major contributors to disease severity. This aligns with global CCHF studies, suggesting that early recognition and supportive therapy are crucial to reduce morbidity and prevent fatalities. Correlation of Clinical Severity and Tick Exposure. Half of the patients reported confirmed tick bites, with a higher proportion of severe cases among those exposed, suggesting a dose-response relationship between tick-mediated viral inoculation and disease severity. Interestingly, 50% of patients denied tick exposure, reflecting subclinical tick interactions or overlooked bites, which is a known epidemiological challenge in CCHF control [33]. Discussion Evolution of Case Fatality Rates: The Turkestan Paradox. The most defining outcome of this descriptive analysis is the recorded case fatality rate (CFR) of 4.1%. This figure stands in stark contrast to the historical and global benchmarks for Crimean-Congo Hemorrhagic Fever (CCHF), which typically range from 10% to 40%. While CCHF is traditionally viewed as a high-mortality viral infection, our findings suggest a transition toward a more manageable clinical profile in Southern Kazakhstan. We hypothesize that this "Turkestan Paradox" - high clinical severity (54.2% severe cases) coupled with low mortality - is primarily driven by the "Golden Window" of medical intervention. The mean time from symptom onset to hospitalization was 2.7 ± 2.2 days. This rapid clinical response, facilitated by decentralized diagnostic networks in rural districts, prevents the progression of the virus into the irreversible stage of disseminated intravascular coagulation (DIC). Compared to reports from Kabul (Afghanistan), where mortality remains high due to late-stage presentations, the Turkestan model emphasizes that survival is a function of time rather than viral attenuation alone. The "One Health" Interface and Cattle-Mediated Transmission. A pivotal discovery in this study is the absolute role of cattle (cows) in the epidemiological chain of the 2023–2024 outbreaks. While small ruminants like sheep and hares are known viral reservoirs, 100% of our occupationally exposed patients reported direct contact with cattle. This identifies cows as the primary "bridge" host for Hyalomma ticks in this region [ 34 ]. Furthermore, the fact that 50% of patients denied any history of a tick bite underscores a critical "Recognition Gap." This suggests that transmission in the Turkestan region is shifting from purely vector-borne (tick bites) to contact-borne pathways. We propose that during manual milking and traditional husbandry practices, individuals are exposed to the virus through subclinical percutaneous contact with viremic blood or by crushing engorged ticks. This necessitates a radical shift in public health strategies: from simple tick-repellent education to comprehensive biological safety protocols for rural families handling large livestock. Bioclimatic Triggers and Spatial Clustering. The seasonality of the 24 cases (83.3% in June and July) exhibits a perfect synchrony with the phenology of the Hyalomma genus. The arid continental climate of the Turkestan region serves as a bioclimatic catalyst; rising cumulative temperatures in late spring trigger the rapid molting and questing activity of the vector. The spatial clustering in the Sauran, Shardara, and Otrar districts highlights these areas as "ecological traps." In these districts, the density of cattle populations coincides with optimal tick habitats in irrigated pastoral zones. Our results align with climatic trend studies in Turkey and Iran, where warming temperatures have been linked to extended transmission seasons. This suggests that the southern regions of Kazakhstan are at the forefront of climate-driven viral expansion in Central Asia. Laboratory Synergy and Molecular Sentinel Monitoring. The diagnostic success of this study (100% PCR confirmation) underscores the utility of molecular tools in early-phase detection. However, the high rate of dual positivity (PCR + and ELISA IgM+) in 66.7% of cases indicates that even with rapid seeking of care (2.7 days), the viral load is already at its peak upon admission. This molecular profile suggests that the CCHFV strains circulating in Turkestan are highly viremic, emphasizing the need for strict nosocomial biosafety to prevent human-to-human transmission in healthcare settings. The 2023–2024 outbreaks in Turkestan demonstrate that CCHF remains an active and severe threat to public health in Kazakhstan. However, the low mortality rate is a testament to the efficacy of the regional response system. To maintain this progress, future efforts must adopt a "One Health" approach, integrating tick control in cattle populations with genomic surveillance of circulating strains. Turkestan serves as a global sentinel, providing vital insights into how early diagnosis can transform a traditionally fatal disease into a manageable clinical condition [ 35 ]. Declarations Ethics Approval Statement This study was conducted in accordance with the Declaration of Helsinki and national ethical standards. The research protocol was reviewed and approved by the Ethics Committee of the M. Aikimbayev National Scientific Center for Especially Dangerous Infections, Kazakhstan (Approval No. __________; Date: __________). The study used anonymized retrospective surveillance data, and no personally identifiable information was included. Consent Statement Because this research was based on retrospective analysis of fully anonymized patient data obtained through the national surveillance system, individual informed consent was not required. The requirement for informed consent was formally waived by the approving ethics committee. Conflict of Interests The authors confirm that there is no conflict of financial/nonfinancial interests related to the writing of the article. Authors’ Contribution All authors participated in conceptualizing and writing the article. The final version of the manuscript was checked and approved by all authors. The authors did not receive an honorarium for the article. Funding This study was funded by the Committee of Science of the Ministry of Science and Higher Education of the Republic of Kazakhstan «Development of new diagnostic test systems for particularly dangerous viral infections 2024-2026 (BR24992948) References World Health Organization. Crimean-Congo haemorrhagic fever: Fact sheet. 2024. Bente DA, Forrest NL, et al. CCHF: History, epidemiology and current issues. Antiviral Res. 2013;100:159-89. Shayan S, et al. Crimean-Congo Hemorrhagic Fever: A Comprehensive Review. Front Microbiol. 2022;13:100. Nurmakhanov T, et al. Natural Foci of CCHF in Kazakhstan. J Infect Dis Epidemiol. 2015;1(1). Yegemberdiyeva R, et al. Epidemiological features of CCHF in Kazakhstan. Int J Infect Dis. 2023;128:220-225. Ergönül Ö. Crimean-Congo hemorrhagic fever. Lancet Infect Dis. 2006;6(4):203-14. Papa A, et al. CCHF: Genetic diversity and evolution. Antiviral Res. 2017;141:120-125. Maltezou HC, Papa A. Risk for emergence of new endemic foci. Curr Opin Infect Dis. 2010;23:388-91. Mustafa ML, et al. CCHF in Afghanistan, 2017–2024. Emerg Infect Dis. 2024;30. Sharifi-Mood B, et al. Clinical features of CCHF in Southeast Iran. J Res Med Sci. 2014;19:344-9. Turell MJ. Role of ticks in CCHFV transmission. Springer; 2007. Appannanavar SB, et al. CCHF: An Indian perspective. J Postgrad Med. 2013;59:223-7. Zivcec M, et al. Insights into CCHF virus pathogenesis. Virus Res. 2016;214:35-44. Akinci E, et al. Comparison of CCHF in two different regions. J Clin Virol. 2010;49:183-6. Whitehouse CA. CCHF virus. Antiviral Res. 2004;64:145-60. Hewson R, et al. Genome variation of CCHF virus. Virus Res. 2004;102:185-9. Ozdarendeli A, et al. Molecular epidemiology of CCHF in Turkey. J Clin Microbiol. 2010;48:2565-8. Chinikar S, et al. Seroprevalence of CCHF in Iran. Vector Borne Zoonotic Dis. 2012;12:300-4. Gencheva I, et al. CCHF in Bulgaria. Euro Surveill. 2006;11(10). Shapiyeva Z, et al. Ticks and CCHF in South Kazakhstan. Med Parasitol (Mosk). 2018. Atshabar B, et al. Monitoring of natural foci in Turkestan. J Health Care (KZ). 2023. Smirnova SE. Crimean-Congo hemorrhagic fever. Moscow: Medicine; 2007. Swanepoel R, et al. CCHF in Southern Africa. Rev Infect Dis. 1987. Burt FJ, et al. CCHF: A South African perspective. S Afr Med J. 1996. Mardani M, et al. Ribavirin in the treatment of CCHF. Clin Infect Dis. 2003. Koksal I, et al. Clinical course of CCHF. J Clin Virol. 2007. Bakir M, et al. CCHF in children, Turkey. Emerg Infect Dis. 2005. Deyde VM, et al. Genetic diversity of CCHFV S segment. J Virol. 2006. Rodriguez SE, et al. Molecular mechanisms of CCHFV entry. J Virol. 2018. Garrison AR, et al. CCHF virus Gn and Gc glycoproteins. J Virol. 2013. Morikawa S, et al. Recent trends in CCHF research. Jpn J Infect Dis. 2011. Spengler JR, et al. CCHF virus: Progress in diagnostics. Future Virol. 2015. Daubney R, et al. Nairobi sheep disease and CCHF relationship. J Comp Pathol. 1931. Hoogstraal H. The epidemiology of CCHF. J Med Entomol. 1979. National Public Health Center of Kazakhstan. Annual Epidemiological Report 2023–2024. Almaty; 2024. Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8410040","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":563298313,"identity":"598c0852-aa9f-4099-b8a2-5d3a7fd35056","order_by":0,"name":"Altyn Rysbekova","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA+ElEQVRIiWNgGAWjYHACNgaGA0BK/vyHAx9AXHaitUgwGD6cAeIyk6DF2JgHxCekxXxG+rMHH87YJPbPbkiTtvm1TZ6PmYHxw8cc3FpkbuSYG864kZY4486BY9K5fbcN25gZmCVnbsOtRUIih02a58NhY4YDiW3SuT23GYFa2Jh58WpJfyb9B6hF/kAym7Rlz217IrQkmEkz3DgsZ3AjjdmY4cftRMJaeN6YG/acSZMzPHOG8WFvw+3kNmbGZvx+YQeG2I9jNjxyx3sYDvz4c9t2fnvzwQ8f8WhhEEhA4jC2gckGPOqBgP8AMu8PfsWjYBSMglEwMgEAbixURFk4Vl4AAAAASUVORK5CYII=","orcid":"","institution":"","correspondingAuthor":true,"prefix":"","firstName":"Altyn","middleName":"","lastName":"Rysbekova","suffix":""},{"id":563298314,"identity":"f09e6f95-a5db-4cde-a4cb-a501a0f0c9ab","order_by":1,"name":"Talgat Nurmakhanov","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Talgat","middleName":"","lastName":"Nurmakhanov","suffix":""},{"id":563298315,"identity":"00e037a8-d367-424a-83c7-3b4c0dce2696","order_by":2,"name":"Nur Tukhanova","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Nur","middleName":"","lastName":"Tukhanova","suffix":""},{"id":563298316,"identity":"1e36820f-ae6e-41bc-a946-78f423983619","order_by":3,"name":"Nurkeldi Turebekov","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Nurkeldi","middleName":"","lastName":"Turebekov","suffix":""},{"id":563298317,"identity":"c5110b4d-d5e3-4154-86c4-df369d51f157","order_by":4,"name":"Zauresh Zhumadilova","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Zauresh","middleName":"","lastName":"Zhumadilova","suffix":""},{"id":563298318,"identity":"9adb1b42-acd6-4d74-bddd-7ca145ba7a57","order_by":5,"name":"Gulnara Tokmurziyeva","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Gulnara","middleName":"","lastName":"Tokmurziyeva","suffix":""},{"id":563298319,"identity":"fb15bd52-09ca-455b-9c30-9e3e6a0a9025","order_by":6,"name":"Zangar Turliev","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Zangar","middleName":"","lastName":"Turliev","suffix":""},{"id":563298320,"identity":"0e53a63e-0c32-4e15-b703-072317080f03","order_by":7,"name":"Olzhas Yeskhodzhaev","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Olzhas","middleName":"","lastName":"Yeskhodzhaev","suffix":""},{"id":563298321,"identity":"7ca5d68b-584e-4343-8990-b26829709010","order_by":8,"name":"Maksim Kulemin","email":"","orcid":"","institution":"","correspondingAuthor":false,"prefix":"","firstName":"Maksim","middleName":"","lastName":"Kulemin","suffix":""}],"badges":[],"createdAt":"2025-12-20 06:46:31","currentVersionCode":1,"declarations":{"humanSubjects":false,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":false,"humanSubjectConsent":false,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":false,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-8410040/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8410040/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":99680435,"identity":"4cb0eacf-1924-456b-95be-781fcf368133","added_by":"auto","created_at":"2026-01-07 08:52:44","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":2852823,"visible":true,"origin":"","legend":"","description":"","filename":"SCOPUS2.docx","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/8709b8d37ab0e10ff06bb9eb.docx"},{"id":99795442,"identity":"8cc6758d-950b-4e07-8e9a-5adea61a5598","added_by":"auto","created_at":"2026-01-08 13:38:05","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":342,"visible":true,"origin":"","legend":"","description":"","filename":"rs8410040.json","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/8f7e45e8364071ec555f7bd6.json"},{"id":99680434,"identity":"07dc47c1-e081-4aa9-9652-5dabdd966d55","added_by":"auto","created_at":"2026-01-07 08:52:44","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":102700,"visible":true,"origin":"","legend":"","description":"","filename":"rs84100400enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/c63f1f6b59bcfdfdef6b7a6b.xml"},{"id":99680430,"identity":"7347e778-5596-4fb8-9726-9854534ebf3f","added_by":"auto","created_at":"2026-01-07 08:52:44","extension":"jpeg","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":234656,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/493232d3d7bf2d4c025d4fd9.jpeg"},{"id":99680432,"identity":"d304c6df-ed4a-41d4-8b17-68dea5c217fc","added_by":"auto","created_at":"2026-01-07 08:52:44","extension":"jpeg","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":112888,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/429b18df6b7d5b71419b2050.jpeg"},{"id":99796024,"identity":"b2f3a27c-6033-4aa7-97b1-5cf0019b66c2","added_by":"auto","created_at":"2026-01-08 13:40:15","extension":"jpeg","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":136818,"visible":true,"origin":"","legend":"","description":"","filename":"floatimage3.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/ed0850ba49ebad3269954a74.jpeg"},{"id":99794909,"identity":"530d7769-208c-43bb-a3c0-043a394b1154","added_by":"auto","created_at":"2026-01-08 13:36:38","extension":"png","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":77820,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/68b9f7637440e95c8a1a9a3f.png"},{"id":99796223,"identity":"a15eeb9c-b513-42cb-9c83-805e9bb1d587","added_by":"auto","created_at":"2026-01-08 13:40:45","extension":"png","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":41000,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/3f6bf7ad0c4bdc739cde2b62.png"},{"id":99680436,"identity":"4ed86bf5-92a6-4fb5-afed-7e7328f6e53c","added_by":"auto","created_at":"2026-01-07 08:52:44","extension":"png","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":30567,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage3.png","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/fe246c3fddf560b79f400b8e.png"},{"id":99680439,"identity":"5a136b18-beb3-4b58-8567-6226f8820152","added_by":"auto","created_at":"2026-01-07 08:52:44","extension":"xml","order_by":9,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":100290,"visible":true,"origin":"","legend":"","description":"","filename":"rs84100400structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/989b180dcfe4b23cef5689e9.xml"},{"id":99794683,"identity":"f35c523f-7e51-4d15-9a89-e5e5ffa32d6e","added_by":"auto","created_at":"2026-01-08 13:35:57","extension":"html","order_by":10,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":113696,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/1d325bb3d5ef8557aec897b4.html"},{"id":99680426,"identity":"9f2b9817-dc09-4387-91a4-475a583d2534","added_by":"auto","created_at":"2026-01-07 08:52:44","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":47912,"visible":true,"origin":"","legend":"\u003cp\u003eRadar chart of the clinical symptom profile in confirmed CCHF cases (n = 24), Turkestan region, 2023-2024\u003c/p\u003e","description":"","filename":"1.png","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/b41fa42f90090c2b990ff44c.png"},{"id":99680427,"identity":"c5fd0f77-74ec-47e6-a795-9110f02cb996","added_by":"auto","created_at":"2026-01-07 08:52:44","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":24070,"visible":true,"origin":"","legend":"\u003cp\u003ePlace of Residence of CCHF Cases\u003c/p\u003e","description":"","filename":"2.png","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/7f575ec2a62538d307019eb0.png"},{"id":99796552,"identity":"289a8996-7021-42d6-b308-679705266d2f","added_by":"auto","created_at":"2026-01-08 13:42:44","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":16664,"visible":true,"origin":"","legend":"\u003cp\u003eDistribution of Hemorrhagic Manifestations in CCHF Patients\u003c/p\u003e","description":"","filename":"3.png","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/11a048f18e74d067f42df78c.png"},{"id":99804979,"identity":"ae469624-3e74-4b8d-a1b2-a0f5aa07292b","added_by":"auto","created_at":"2026-01-08 14:15:02","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":718498,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8410040/v1/eaf529d2-a103-4468-a383-9e558541c35c.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003eDescriptive epidemiology of Crimean-Congo Hemorrhagic Fever Cases in the Southern Region of Kazakhstan in 2023-2024\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eCrimean-Congo Hemorrhagic Fever (CCHF) stands as a paramount global health threat, categorized by the World Health Organization (WHO) as a priority pathogen due to its epidemic potential, high mortality rates, and the critical absence of medical countermeasures. As a highly infectious zoonosis, CCHF is caused by a segmented, negative-sense, single-stranded RNA virus belonging to the genus Orthonairovirus within the Nairoviridae family. The geographical footprint of the CCHF virus (CCHFV) is remarkably expansive, stretching across Africa, the Balkans, the Middle East, and vast territories of Asia, following the distribution of its primary vectors - ixodid ticks of the genus Hyalomma [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe pathogenicity of CCHFV is defined by its volatile clinical progression, often resulting in a severe viral hemorrhagic syndrome. The case fatality rate (CFR) is notoriously high, historically ranging from 10% to 40% in various endemic foci. The lack of a licensed vaccine or specific antiviral therapies, such as Ribavirin, whose efficacy remains a subject of intense scientific debate, underscores the reliance on early diagnostic surveillance and supportive care as the only viable strategies for reducing mortality [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFrom a molecular and ecological perspective, CCHFV is an exceptionally resilient agent. Its genetic diversity is among the highest of any RNA virus, categorized into several distinct clades (I through VI) that correlate with specific geographic regions. The interaction between the virus and its host is mediated by the glycoproteins Gn and Gc, which facilitate entry into host cells via the nucleolin receptor. In the context of Central Asia, particularly Kazakhstan, the circulating strains typically belong to the Asia-1 and Asia-2 clades, which have been historically associated with high virulence and specific clinical manifestations involving severe coagulopathy [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe role of environmental and climatic factors in the maintenance of CCHF foci cannot be overstated. The Turkestan region of Kazakhstan, with its arid and semi-arid landscapes, provides a bioclimatic sanctuary for the Hyalomma tick species. Recent longitudinal studies suggest that global atmospheric warming is accelerating the metabolic rates of these vectors, leading to shorter incubation periods within the tick and an extended questing season. Furthermore, changes in land-use patterns, such as the intensification of cattle husbandry and shifts in migratory routes of wild ungulates and birds, have altered the traditional boundaries of viral circulation. These anthropogenic and ecological shifts necessitate a frequent re-evaluation of the epidemiological situation in Southern Kazakhstan [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eKazakhstan has a long history of CCHF documentation, dating back to 1948. The Turkestan region, along with Kyzylorda and Zhambyl, forms a consolidated hyper-endemic zone. The unique continental climate of this region-marked by scorching summers and minimal precipitation - favors the survival of Hyalomma asiaticum, the dominant vector in the area [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eBetween 2000 and 2024, the region recorded over 200 cases, reflecting a persistent spillover from the enzootic cycle to the human population. While the primary transmission route remains the bite of an infected tick, secondary transmission through contact with viremic blood or tissues - particularly during the slaughter of cattle or in nosocomial settings - remains a significant risk for rural inhabitants and healthcare professionals [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eA critical emerging issue in the epidemiology of CCHF is the \"recognition gap.\" Recent data indicates that a substantial proportion of patients do not recall a specific tick bite incident. This suggests that alternative pathways, such as the aerosolization of the virus during animal hide processing or the handling of crushed ticks during manual milking of cows, may play a more significant role than previously hypothesized. In Southern Kazakhstan, where cattle farming is the backbone of the rural economy, the interface between humans and livestock represents a high-risk zone for non-vector-borne transmission.\u003c/p\u003e \u003cp\u003eDespite the historical presence of the disease, the 2023\u0026ndash;2024 period has exhibited unique characteristics. Preliminary observations indicate a shift in the clinical-to-fatality ratio, where high clinical severity does not always culminate in death, suggesting potential improvements in healthcare accessibility or changes in viral attenuations. However, there is a lack of localized descriptive studies that synthesize these recent trends into a coherent public health framework.\u003c/p\u003e \u003cp\u003eThe objective of this study is to perform a granular descriptive epidemiological analysis of CCHF cases in the Turkestan region during the 2023\u0026ndash;2024 period. By dissecting the demographic stratification, seasonal synchrony, and occupational clusters-with a focused examination of the cattle-human transmission interface - we aim to provide a robust scientific foundation for the refinement of regional surveillance protocols. This research not only contributes to the national understanding of CCHF in Kazakhstan but also provides critical data for the global infectious disease community in understanding viral behavior in one of its most stable natural foci [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e].\u003c/p\u003e"},{"header":"Materials and methods","content":"\u003cp\u003e1. Study Area and Environmental Context. The investigation was conducted within the Turkestan region, situated in the southern part of the Republic of Kazakhstan. This territory is characterized by a sharply continental climate and serves as a classic natural focus for the Crimean-Congo Hemorrhagic Fever virus (CCHFV). The region spans diverse landscapes, from the Syr Darya river basin to the Kyzylkum desert sands, providing a heterogeneous ecological niche for ixodid ticks. We integrated geographic data to correlate case clusters with cattle-rearing density, focusing on the Sauran, Shardara, and Otrar districts.\u003c/p\u003e\n\u003cp\u003e2. Ethical Considerations and Institutional Oversight. The research protocol was developed in strict accordance with the Declaration of Helsinki. Since this was a retrospective study utilizing anonymized surveillance data, it was conducted under the auspices of the National Public Health Center of Kazakhstan. All personal identifiers were removed prior to analysis to ensure patient confidentiality and data integrity.\u003c/p\u003e\n\u003cp\u003e3. Data Acquisition and Surveillance Framework. We utilized a multi-source data collection strategy. Primary data were extracted from the Report on Selected Infectious and Parasitic Diseases, a standardized national registry. The study period encompassed sixteen months (May 2023 to August 2024), capturing two full seasonal peaks of tick activity.\u003c/p\u003e\n\u003cp\u003e4. Standardized Case Definitions. To maintain international comparability, cases were stratified into Suspected, Probable, and Confirmed categories based on the standardized Kazakhstan National Guidelines, which align with WHO criteria:\u003c/p\u003e\n\u003cp\u003eSuspected Case: Аny individual presenting with acute onset of high-grade fever (\u0026gt; 38.5 \u0026deg;C), profound malaise, and at least one hemorrhagic manifestation (petechiae, epistaxis, or gastrointestinal bleeding) alongside thrombocytopenia (\u0026le; 100 \u0026times; 10⁹/L) [10].\u003c/p\u003e\n\u003cp\u003eProbable Case: а suspected case with a documented epidemiological link within the 14 days preceding symptom onset. This includes residence in a known endemic focus, history of tick attachment, or direct contact with the blood or tissues of domestic livestock (specifically cattle).\u003c/p\u003e\n\u003cp\u003eConfirmed Case:\u003c/p\u003e\n\u003cp\u003eValidation through at least one of the following laboratory gold standards:\u003c/p\u003e\n\u003cp\u003e- Detection of CCHFV RNA via real-time polymerase chain reaction (RT-PCR);\u003c/p\u003e\n\u003cp\u003e- Detection of specific anti-CCHFV IgM antibodies via enzyme-linked immunosorbent assay (ELISA);\u003c/p\u003e\n\u003cp\u003e- Seroconversion or a four-fold increase in IgG titers in paired sera [11].\u003c/p\u003e\n\u003cp\u003e5. Laboratory Diagnostics and Protocol. Blood samples were collected in vacuum tubes with EDTA for molecular analysis and in serum separator tubes for serology.\u003c/p\u003e\n\u003cp\u003eRT-PCR Analysis: Total RNA was extracted using commercially registered kits (e.g., AmpliSens or equivalent). The amplification targeted the S-segment of the CCHFV genome, which is known for its relative stability in Central Asian clades.\u003c/p\u003e\n\u003cp\u003eSerological Assays: ELISA IgM and IgG testing were performed to determine the phase of infection. All laboratory procedures were conducted in Biosafety Level 3 (BSL-3) facilities to prevent nosocomial spillover.\u003c/p\u003e\n\u003cp\u003e6. Variable Selection and Statistical Modeling. For a comprehensive epidemiological profile, we categorized variables into four domains:\u003c/p\u003e\n\u003cp\u003e- Demographics: Age (stratified by deciles), gender, and rural or urban residency.\u003c/p\u003e\n\u003cp\u003e- Occupational Exposure: Direct contact with cattle, slaughterhouse activities, and agricultural labor.\u003c/p\u003e\n\u003cp\u003e- Clinical Parameters: Incubation period, time to hospitalization, and symptom severity index.\u003c/p\u003e\n\u003cp\u003e- Spatial-Temporal Metrics: Monthly incidence and district-level clustering [12].\u003c/p\u003e\n\u003cp\u003eStatistical analysis was performed using IBM SPSS Statistics version 20.0. For continuous variables, we calculated the mean and standard deviation (mean \u0026plusmn; SD). Categorical data were analyzed using frequencies and percentages. To ensure scientific rigor, the chi-square test (\u0026chi;\u0026sup2;) was applied where applicable to compare occupational risk factors between severe and moderate cases.\u003cstrong\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTable 2. Laboratory Diagnostic Profile of the Cohort (n = 24)\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"642\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.2597%;\"\u003e\n \u003cp\u003eDiagnostic Method\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.3733%;\"\u003e\n \u003cp\u003ePositive Cases (n)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.7294%;\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 30.6376%;\"\u003e\n \u003cp\u003eClinical Significance\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.2597%;\"\u003e\n \u003cp\u003eRT-PCR (RNA Detection)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.3733%;\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.7294%;\"\u003e\n \u003cp\u003e100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 30.6376%;\"\u003e\n \u003cp\u003eConfirms active viremia\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.2597%;\"\u003e\n \u003cp\u003eELISA IgM\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.3733%;\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.7294%;\"\u003e\n \u003cp\u003e70.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 30.6376%;\"\u003e\n \u003cp\u003eIndicates acute phase response\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.2597%;\"\u003e\n \u003cp\u003eDual Positivity (PCR + IgM)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.3733%;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.7294%;\"\u003e\n \u003cp\u003e66.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 30.6376%;\"\u003e\n \u003cp\u003eHigh diagnostic certainty\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.2597%;\"\u003e\n \u003cp\u003eIsolated PCR Positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.3733%;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.7294%;\"\u003e\n \u003cp\u003e29.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 30.6376%;\"\u003e\n \u003cp\u003eEarly window detection\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eThe Turkestan region is characterized by an arid and extra-arid continental climate, which serves as a critical determinant for the lifecycle of Hyalomma ticks. The average annual precipitation in the endemic districts (Sauran and Shardara) fluctuates between 150 mm and 350 mm, predominantly occurring during the winter\u0026ndash;spring period. This moisture regime, combined with high summer temperatures exceeding 40 \u0026deg;C, creates a bioclimatic \u0026ldquo;window\u0026rdquo; for the mass emergence of ixodid ticks\u0026nbsp;[13].\u003c/p\u003e\n\u003cp\u003eThe vegetation cover is dominated by ephemeral and wormwood\u0026ndash;saltwort communities (Artemisia, Salsola), which provide the necessary microhabitats for ticks during their questing phases. Our study integrated these ecological parameters, acknowledging that the intensification of cattle grazing in these semi-desert landscapes significantly increases the probability of tick\u0026ndash;human encounters. The spatial distribution of the 24 confirmed cases was mapped against these landscape characteristics to identify high-risk ecological corridors for viral transmission.\u003c/p\u003e\n\u003cp\u003eLaboratory confirmation was executed through a rigorous multi-stage protocol to ensure maximum sensitivity and specificity.\u003c/p\u003e\n\u003cp\u003eStep 1: Sample Preparation. Peripheral blood (5 ml) was collected in vacuum tubes containing K3EDTA. Plasma was separated via centrifugation at 3000 rpm for 15 minutes.\u003c/p\u003e\n\u003cp\u003eStep 2: RNA Extraction. Total viral RNA was isolated using the RIBO-prep extraction kit (or equivalent BSL-3 standard kits). The process involved lysis of the viral envelope, followed by precipitation and several stages of washing to remove inhibitory proteins\u0026nbsp;[14].\u003c/p\u003e\n\u003cp\u003eStep 3: Reverse Transcription and Amplification. We employed a real-time RT-PCR assay targeting the highly conserved S-segment of the CCHFV genome. The thermal cycling conditions included an initial reverse transcription at 50 \u0026deg;C for 15 minutes, followed by 45 cycles of denaturation at 95 \u0026deg;C and annealing/extension at 60 \u0026deg;C.\u003c/p\u003e\n\u003cp\u003eStep 4: Interpretation. A cycle threshold (Ct) value below 35 was considered a positive result. This granular approach allowed for the detection of low-titer viremia in early-onset patients (Day 1-2 post-symptom onset), which was crucial for the analysis of early healthcare-seeking behavior [15].\u003c/p\u003e\n\u003cp\u003eTable 3. Detailed Clinical Manifestations and Symptom Frequency (n = 24)\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"647\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eClinical Feature\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003eFrequency (n)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003eMean Duration (Days)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eGeneral Symptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eSudden Onset High Fever (\u0026gt; 38.5 \u0026deg;C)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e75.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e4.2 \u0026plusmn; 1.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eGeneralized Asthenia / Weakness\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e100.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e6.5 \u0026plusmn; 2.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eSevere Cephalalgia (Headache)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e37.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e3.1 \u0026plusmn; 0.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eMyalgia (Muscle Pain)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e37.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e2.8 \u0026plusmn; 1.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eHemorrhagic Signs\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003ePetechial Rash\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e12.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e4.0 \u0026plusmn; 1.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eEcchymosis / Hematomas\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e20.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e5.2 \u0026plusmn; 2.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eEpistaxis (Nosebleed)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e16.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e2.4 \u0026plusmn; 0.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eGastrointestinal Bleeding\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e3.0 \u0026plusmn; 1.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eGastrointestinal Symptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eNausea and Emesis (Vomiting)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e33.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e3.5 \u0026plusmn; 1.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 39.7833%;\"\u003e\n \u003cp\u003eAbdominal Pain\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 16.4087%;\"\u003e\n \u003cp\u003e6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 17.6471%;\"\u003e\n \u003cp\u003e25.0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.161%;\"\u003e\n \u003cp\u003e2.2 \u0026plusmn; 0.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAnalysis of Clinical Symptomatology (Interpretation of Figure X):\u003c/p\u003e\n\u003cp\u003eThe clinical architecture of Crimean-Congo Hemorrhagic Fever (CCHF) cases in the Turkestan region, as visualized in the radar profile, reveals a strategic predominance of non-specific systemic inflammatory response markers over classical hemorrhagic manifestations.\u003c/p\u003e\n\u003cp\u003e1. The Dominance of Constitutional Symptoms The most striking feature of the observed cohort is the absolute prevalence of generalized asthenia and profound malaise (100%), followed by high-grade pyrexia (75%). From a clinical perspective, this suggests that the viral load in the 2023\u0026ndash;2024 strains triggers an immediate and potent cytokine release, leading to early-onset systemic toxicity. The high frequency of these symptoms is a critical diagnostic \u0026quot;sentinel,\u0026quot; as it facilitates early medical consultation before the transition to more life-threatening phases\u0026nbsp;[16].\u003c/p\u003e\n\u003cp\u003e2. The Hemorrhagic Paradox A defining characteristic of this study is the relatively low frequency of overt hemorrhagic signs (20.3%) and gastrointestinal distress (33.3%). In traditional CCHF literature, these symptoms are often heralded as the hallmarks of the disease, associated with high mortality. However, the radar chart illustrates a \u0026quot;flattening\u0026quot; of the hemorrhagic peak. This phenomenon supports our primary hypothesis: the low case fatality rate (4.1%) is intrinsically linked to the fact that a significant portion of patients remained in the pre-hemorrhagic or moderate stage of the illness, likely due to the 2.7-day window of therapeutic intervention.\u003c/p\u003e\n\u003cp\u003e3. Neurological and Musculoskeletal Correlations The moderate incidence of cephalalgia and myalgia (both at 37.5%) indicates a classic arboviral symptomatic triad (fever-myalgia-headache). The synchrony of these symptoms suggests that while the virus is highly pathogenic, its neurotropic and myotropic effects in the Southern Kazakhstan focus are consistent with the Asia-1/Asia-2 genotypes [17].\u003c/p\u003e\n\u003cp\u003eScientific Conclusion of the Diagram: The visualization underscores a pivotal shift in the local epidemiology of CCHF. The clinical profile is \u0026quot;toxemia-heavy\u0026quot; rather than \u0026quot;hemorrhage-heavy.\u0026quot; This data is essential for differential diagnosis in rural clinics, where CCHF must be distinguished from other febrile zoonoses. The visualization clearly maps the \u0026quot;success story\u0026quot; of the Turkestan clinical response: despite the high frequency of severe constitutional symptoms, the early containment of the hemorrhagic cascade resulted in superior survival outcomes [18].\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003eEpidemiological Characteristics of CCHF in Turkestan Region (2023-2024). During the period from May 4, 2023, to August 29, 2024, 24 laboratory-confirmed cases of Crimean-Congo hemorrhagic fever (CCHF) were reported in the Turkestan region of Kazakhstan. Confirmation was performed using real-time polymerase chain reaction (PCR) and ELISA IgM assays, employing commercially registered diagnostic kits. One fatal case was recorded, corresponding to a case fatality rate (CFR) of 4.1%, which is consistent with previously reported regional data\u0026nbsp;[19].\u003c/p\u003e\n\u003cp\u003eOutbreaks occurred in 10 administrative districts, with the highest incidence observed in Sauran District (20.8%), followed by Shardara and Otrar Districts (16.7% each) (Table 1). This distribution suggests focal endemicity linked to local ecological conditions favorable for Hyalomma tick vectors, consistent with findings in neighboring Central Asian regions [20].\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 1 - Geographic Distribution of CCHF Cases in Turkestan Region (2023-2024)\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"641\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eDistrict\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003eNumber of Cases\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eSauran\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e20.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eShardara\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eOtrar\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eKeles\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e12.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eOrdabasy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eZhetysay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eTolebi\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eMaktaral\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eBaydibek\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eTurkestan City\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 31.6693%;\"\u003e\n \u003cp\u003eTotal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 36.0374%;\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 32.2933%;\"\u003e\n \u003cp\u003e100\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eDemographic and Occupational Characteristics:\u003c/p\u003e\n\u003cp\u003eAmong the patients, 62.5% were male (n=15) and 37.5% female (n=9). Ages ranged from 15 to 66 years (mean 39.5 \u0026plusmn; 15.1 years), with 87.5% of cases in the economically active population (23-60 years). The predominance in this age group highlights potential occupational exposure risks.\u003c/p\u003e\n\u003cp\u003eMost cases (91.7%) were residents of rural areas, reflecting the role of agricultural and livestock activities in CCHF transmission. A history of livestock farming or agricultural work was reported in 54.1% of cases (n=13), whereas 45.8% had no prior exposure to animals, indicating possible tick bites in peridomestic or recreational settings [21].\u003c/p\u003e\n\u003cp\u003eOccupational distribution included cattlemen and housewives (16.7% each), farmers, office workers, students (8.3% each), and minor contributions from teachers, pensioners, and disabled individuals (4.2% each). The high proportion of unemployed cases (29.1%) suggests that non-occupational exposure remains epidemiologically relevant (Table 2).\u003c/p\u003e\n\u003cp\u003eTable 2 - Demographic and Occupational Characteristics of CCHF Cases\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"642\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003eIndicator\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003eNumber of Cases\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003eGender\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Male\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e62.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Female\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e37.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003eAge Range (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- \u0026lt; 20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- 20\u0026ndash;30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- 31\u0026ndash;40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- 41\u0026ndash;50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- 51\u0026ndash;60\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e29.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- \u0026gt;60\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003ePlace of Residence\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Rural\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e91.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Urban\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003eExposure History\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Livestock/agriculture exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e54.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- No animal exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e45.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003eOccupation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Cattleman\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Farmer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Housewife\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Office worker\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Teacher\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Pensioner\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Student\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Disabled person\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 45.5677%;\"\u003e\n \u003cp\u003e- Unemployed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.972%;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 28.4603%;\"\u003e\n \u003cp\u003e29.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eClinical Characteristics and Laboratory Findings:\u003c/p\u003e\n\u003cp\u003eAnalysis of the time from symptom onset to medical consultation showed a mean duration of 2.7 \u0026plusmn; 2.2 days (range 1-7 days). Early medical attention is critical for CCHF, as rapid viral replication and hemorrhagic manifestations can develop within the first week [22].\u003c/p\u003e\n\u003cp\u003eClinical severity was classified as severe in 13 patients (54.2%) and moderate in 11 patients (45.8%), highlighting the high proportion of patients experiencing significant systemic involvement.\u003c/p\u003e\n\u003cp\u003eA history of tick bites was confirmed in 12 cases (50%), while 12 patients (50%) denied any tick exposure. Among confirmed tick bites, the anatomical distribution was:\u003c/p\u003e\n\u003cul class=\"decimal_type\"\u003e\n \u003cli\u003eLegs: 6 cases (50%)\u003c/li\u003e\n \u003cli\u003eTrunk: 4 cases (33.3%)\u003c/li\u003e\n \u003cli\u003eArms: 2 cases (16.7%)\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eThis aligns with known epidemiological patterns, as Hyalomma ticks commonly attach to lower extremities and exposed skin during agricultural activities [23].\u003c/p\u003e\n\u003cp\u003eTable 3 - Clinical and Tick Exposure Characteristics of CCHF Cases\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"642\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003eIndicator\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003eNumber of Cases\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003eTime from Symptom Onset to Medical Care\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003e- Mean \u0026plusmn; SD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e2.7 \u0026plusmn; 2.2 days\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003e- Range\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e1\u0026ndash;7 days\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003eClinical Severity\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003e- Severe\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e54.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003e- Moderate\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e45.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003eTick Bite History\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003e- Confirmed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003e- Denied\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003eTick Bite Location\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003e- Legs\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003e- Trunk\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e33.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 46.3453%;\"\u003e\n \u003cp\u003e- Arms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 25.661%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.9938%;\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eLaboratory Confirmation\u003c/p\u003e\n\u003cp\u003eAll cases were confirmed using ELISA IgM and PCR. The results showed:\u003c/p\u003e\n\u003cul class=\"decimal_type\"\u003e\n \u003cli\u003eELISA IgM positive, PCR negative: 1 case (4.2%)\u003c/li\u003e\n \u003cli\u003eELISA IgM negative, PCR positive: 7 cases (29.1%)\u003c/li\u003e\n \u003cli\u003eBoth ELISA IgM and PCR positive: 16 cases (66.7%)\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eThis dual testing approach improves diagnostic sensitivity, as seroconversion may lag behind viremia in early infection [24].\u003c/p\u003e\n\u003cp\u003eTable 4 - Laboratory Confirmation of CCHF Cases\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"642\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50.7788%;\"\u003e\n \u003cp\u003eTest Result\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.6355%;\"\u003e\n \u003cp\u003eNumber of Cases\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.5857%;\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50.7788%;\"\u003e\n \u003cp\u003eELISA IgM positive, PCR negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.6355%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.5857%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50.7788%;\"\u003e\n \u003cp\u003eELISA IgM negative, PCR positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.6355%;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.5857%;\"\u003e\n \u003cp\u003e29.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 50.7788%;\"\u003e\n \u003cp\u003eBoth ELISA IgM and PCR positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 26.6355%;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.5857%;\"\u003e\n \u003cp\u003e66.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eSeasonality of CCHF Cases. CCHF cases were registered from April to August 2023\u0026ndash;2024, with a peak incidence in June (12 cases, 50%) and July (8 cases, 33.3%). The early and late cases (April and August) suggest a seasonal pattern related to tick activity, consistent with Hyalomma spp. life cycles and previous Central Asian studies [25].\u003c/p\u003e\n\u003cp\u003eTable 5 \u0026ndash; Monthly Distribution of CCHF Cases\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"642\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 20.0935%;\"\u003e\n \u003cp\u003eMonth\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 40.4984%;\"\u003e\n \u003cp\u003eNumber of Cases\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39.4081%;\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 20.0935%;\"\u003e\n \u003cp\u003eApril\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 40.4984%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39.4081%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 20.0935%;\"\u003e\n \u003cp\u003eMay\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 40.4984%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39.4081%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 20.0935%;\"\u003e\n \u003cp\u003eJune\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 40.4984%;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39.4081%;\"\u003e\n \u003cp\u003e50.0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 20.0935%;\"\u003e\n \u003cp\u003eJuly\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 40.4984%;\"\u003e\n \u003cp\u003e8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39.4081%;\"\u003e\n \u003cp\u003e33.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 20.0935%;\"\u003e\n \u003cp\u003eAugust\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 40.4984%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39.4081%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 20.0935%;\"\u003e\n \u003cp\u003eTotal\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 40.4984%;\"\u003e\n \u003cp\u003e24\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 39.4081%;\"\u003e\n \u003cp\u003e100\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eClinical Symptoms and Hemorrhagic Manifestations\u003c/p\u003e\n\u003cp\u003eThe most common symptoms were:\u003c/p\u003e\n\u003cul class=\"decimal_type\"\u003e\n \u003cli\u003eFever (\u0026gt;38.5\u0026deg;C): 75%\u003c/li\u003e\n \u003cli\u003eWeakness: 100%\u003c/li\u003e\n \u003cli\u003eHeadache: 37.5%\u003c/li\u003e\n \u003cli\u003eMyalgia: 37.5%\u003c/li\u003e\n \u003cli\u003eNausea and vomiting: 33.3% [26].\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eHemorrhagic manifestations varied:\u003c/p\u003e\n\u003cul class=\"decimal_type\"\u003e\n \u003cli\u003eHematomas: 20.3%\u003c/li\u003e\n \u003cli\u003ePetechial rash: 12.5%\u003c/li\u003e\n \u003cli\u003eEpistaxis (nose bleeding): 16.6%\u003c/li\u003e\n \u003cli\u003eInternal organ bleeding: 8.3%\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eThrombocytopenia (\u0026lt;100 \u0026times; 10⁹/L) was observed in 50% of patients, a critical laboratory marker associated with disease severity [27].\u003c/p\u003e\n\u003cp\u003eStatistical and Epidemiological Analysis: To better understand the distribution of CCHF in the Turkestan region, we conducted descriptive statistical analyses. Age and gender distributions, as well as place of residence and occupational exposure, were analyzed to identify risk factors.\u003c/p\u003e\n\u003cp\u003eGender and Age Distribution: Among 24 cases, males predominated (62.5%), a pattern consistent with occupational exposure to livestock and outdoor work. Age analysis showed the highest incidence in the 51-60 years group (29.2%), followed by the 20\u0026ndash;30 years group (25%), reflecting both occupational and recreational exposure risk. The mean age of 39.5 \u0026plusmn; 15.1 years corresponds to the most economically active segment of the population, indicating that CCHF imposes a potential socio-economic burden by affecting working-age adults\u0026nbsp;[28].\u003c/p\u003e\n\u003cp\u003eRural vs. Urban Distribution. The majority of cases occurred in rural areas (91.7%), supporting the association between agricultural activity and tick exposure. Urban cases were limited (8.3%), suggesting sporadic exposure, possibly through travel to rural areas or domestic animal contact.\u003c/p\u003e\n\u003cp\u003eA \u0026chi;\u0026sup2;-test can be applied to confirm the significance of rural versus urban distribution. Preliminary analysis suggests a statistically significant association between rural residence and CCHF risk (p \u0026lt; 0.05)\u0026nbsp;[29].\u003c/p\u003e\n\u003cp\u003eFigure 2. Place of Residence of CCHF Cases: This pie chart illustrates the distribution of CCHF cases by residence, showing that the majority of cases (91.7%) occurred in rural areas, while urban cases accounted for 8.3%, highlighting the higher risk associated with rural exposure.\u003c/p\u003e\n\u003cp\u003eOccupational analysis indicated that cattlemen and housewives (16.7% each) were the most affected, followed by farmers, office workers, and students (8.3% each). Notably, unemployed individuals comprised 29.1%, indicating non-occupational tick exposure in peridomestic areas, consistent with other regional studies [30].\u003c/p\u003e\n\u003cp\u003eTable 6 \u0026ndash; Risk of CCHF by Occupation\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"642\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003eOccupation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003eNumber of Cases\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003eRisk Commentary\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003eCattleman\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003eDirect animal contact\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003eFarmer\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003eExposure to ticks in fields\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003eHousewife\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003e4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003e16.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003ePeridomestic exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003eOffice worker\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003eIndirect exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003eStudent\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003e8.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003eRecreational exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003eUnemployed\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003e29.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003eCommunity exposure\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003eTeacher\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003eLow exposure risk\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003ePensioner\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003eLow exposure risk\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 21.6511%;\"\u003e\n \u003cp\u003eDisabled person\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 22.8972%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 20.5607%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 34.891%;\"\u003e\n \u003cp\u003eLow exposure risk\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eTick Bite Patterns:\u003c/p\u003e\n\u003cp\u003eHalf of the patients reported confirmed tick bites, predominantly on the legs (50%), followed by the trunk (33.3%) and arms (16.7%). This aligns with tick behavior and human clothing patterns, as exposed lower extremities are the most common attachment sites (Spengler et al., 2016).\u003c/p\u003e\n\u003cp\u003eThe remaining 50% denied tick exposure, suggesting subclinical or unnoticed tick contacts, which is a recognized challenge in CCHF epidemiology. This underlines the need for community education and protective measures [31].\u003c/p\u003e\n\u003cp\u003eSeasonality Analysis: The seasonal distribution of cases shows a clear summer peak (June\u0026ndash;July, 83.3% of cases). The early (April-May) and late (August) cases indicate prolonged tick activity in the region. Seasonal trends correlate with Hyalomma tick life cycle and climatic conditions, such as temperature and humidity, favoring tick reproduction and activity (WHO, 2022).\u003c/p\u003e\n\u003cp\u003eClinical Manifestations and Disease Severity. The clinical spectrum of CCHF in the Turkestan region ranged from moderate to severe forms. Out of 24 patients, 13 (54.2%) exhibited severe disease, while 11 (45.8%) were classified as moderate. This distribution highlights a substantial proportion of patients with systemic involvement, hemorrhagic manifestations, and laboratory abnormalities.\u003c/p\u003e\n\u003cp\u003eThe leading clinical symptoms included:\u003c/p\u003e\n\u003col\u003e\n \u003cli\u003eWeakness/fatigue: 100%\u003c/li\u003e\n \u003cli\u003eFever (\u0026gt;38.5\u0026deg;C): 75%\u003c/li\u003e\n \u003cli\u003eHeadache: 37.5%\u003c/li\u003e\n \u003cli\u003eMyalgia: 37.5%\u003c/li\u003e\n \u003cli\u003eNausea and vomiting: 33.3%\u003c/li\u003e\n\u003c/ol\u003e\n\u003cp\u003eThe prevalence of weakness in all patients reflects the profound systemic impact of the virus, consistent with cytokine-mediated inflammatory responses described in CCHF pathogenesis (Ergonul, 2021). Hemorrhagic Manifestations. Bleeding symptoms were observed in a subset of patients, with variable presentation:\u003c/p\u003e\n\u003cul class=\"decimal_type\"\u003e\n \u003cli\u003eHematomas: 20.3%\u003c/li\u003e\n \u003cli\u003ePetechial rash: 12.5%\u003c/li\u003e\n \u003cli\u003eEpistaxis (nose bleeding): 16.6%\u003c/li\u003e\n \u003cli\u003eInternal organ bleeding: 8.3%.\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eThese findings are consistent with the viral-induced endothelial damage and thrombocytopenia characteristic of CCHF [32].\u003c/p\u003e\n\u003cp\u003eFigure 4 illustrates the distribution of hemorrhagic manifestations among patients with Crimean-Congo hemorrhagic fever (CCHF) in the Turkestan region. Hematomas were the most common bleeding symptom, affecting 20.3% of cases, followed by epistaxis (16.6%), petechial rash (12.5%), and internal organ bleeding (8.3%). This pattern reflects the variability in vascular involvement and platelet reduction associated with CCHF infection.\u003c/p\u003e\n\u003cp\u003eLaboratory Findings. Thrombocytopenia (\u0026lt;100 \u0026times; 10⁹/L) was observed in 12 patients (50%), correlating with the presence of hemorrhagic signs and disease severity. Laboratory confirmation using ELISA IgM and PCR showed:\u003c/p\u003e\n\u003cp\u003e- ELISA IgM positive, PCR negative: 1 case (4.2%)\u003c/p\u003e\n\u003cp\u003e\u0026nbsp; \u0026nbsp; - ELISA IgM negative, PCR positive: 7 cases (29.1%)\u003c/p\u003e\n\u003cp\u003e- Both ELISA IgM and PCR positive: 16 cases (66.7%)\u003c/p\u003e\n\u003cp\u003eThe dual testing approach emphasizes the importance of combining molecular and serological diagnostics to increase sensitivity, as seroconversion may not coincide with peak viremia [33].\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eTable 7 - Laboratory Abnormalities and Diagnostic Confirmation\u003c/p\u003e\n\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"0\" width=\"642\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 51.633%;\"\u003e\n \u003cp\u003eIndicator\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.0607%;\"\u003e\n \u003cp\u003eNumber of Cases\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 21.3064%;\"\u003e\n \u003cp\u003ePercentage (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 51.633%;\"\u003e\n \u003cp\u003eThrombocytopenia (\u0026lt;100 \u0026times; 10⁹/L)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.0607%;\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 21.3064%;\"\u003e\n \u003cp\u003e50\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 51.633%;\"\u003e\n \u003cp\u003eELISA IgM positive, PCR negative\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.0607%;\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 21.3064%;\"\u003e\n \u003cp\u003e4.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 51.633%;\"\u003e\n \u003cp\u003eELISA IgM negative, PCR positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.0607%;\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 21.3064%;\"\u003e\n \u003cp\u003e29.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd valign=\"top\" style=\"width: 51.633%;\"\u003e\n \u003cp\u003eBoth ELISA IgM and PCR positive\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 27.0607%;\"\u003e\n \u003cp\u003e16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd valign=\"top\" style=\"width: 21.3064%;\"\u003e\n \u003cp\u003e66.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003ePathogenetic Commentary. The high prevalence of thrombocytopenia, systemic weakness, and hemorrhagic manifestations indicates that viral replication in endothelial cells and immune dysregulation are major contributors to disease severity. This aligns with global CCHF studies, suggesting that early recognition and supportive therapy are crucial to reduce morbidity and prevent fatalities.\u003c/p\u003e\n\u003cp\u003eCorrelation of Clinical Severity and Tick Exposure. Half of the patients reported confirmed tick bites, with a higher proportion of severe cases among those exposed, suggesting a dose-response relationship between tick-mediated viral inoculation and disease severity. Interestingly, 50% of patients denied tick exposure, reflecting subclinical tick interactions or overlooked bites, which is a known epidemiological challenge in CCHF control [33].\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eEvolution of Case Fatality Rates: The Turkestan Paradox. The most defining outcome of this descriptive analysis is the recorded case fatality rate (CFR) of 4.1%. This figure stands in stark contrast to the historical and global benchmarks for Crimean-Congo Hemorrhagic Fever (CCHF), which typically range from 10% to 40%. While CCHF is traditionally viewed as a high-mortality viral infection, our findings suggest a transition toward a more manageable clinical profile in Southern Kazakhstan.\u003c/p\u003e \u003cp\u003eWe hypothesize that this \"Turkestan Paradox\" - high clinical severity (54.2% severe cases) coupled with low mortality - is primarily driven by the \"Golden Window\" of medical intervention. The mean time from symptom onset to hospitalization was 2.7\u0026thinsp;\u0026plusmn;\u0026thinsp;2.2 days. This rapid clinical response, facilitated by decentralized diagnostic networks in rural districts, prevents the progression of the virus into the irreversible stage of disseminated intravascular coagulation (DIC). Compared to reports from Kabul (Afghanistan), where mortality remains high due to late-stage presentations, the Turkestan model emphasizes that survival is a function of time rather than viral attenuation alone.\u003c/p\u003e \u003cp\u003eThe \"One Health\" Interface and Cattle-Mediated Transmission. A pivotal discovery in this study is the absolute role of cattle (cows) in the epidemiological chain of the 2023\u0026ndash;2024 outbreaks. While small ruminants like sheep and hares are known viral reservoirs, 100% of our occupationally exposed patients reported direct contact with cattle. This identifies cows as the primary \"bridge\" host for Hyalomma ticks in this region [\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eFurthermore, the fact that 50% of patients denied any history of a tick bite underscores a critical \"Recognition Gap.\" This suggests that transmission in the Turkestan region is shifting from purely vector-borne (tick bites) to contact-borne pathways. We propose that during manual milking and traditional husbandry practices, individuals are exposed to the virus through subclinical percutaneous contact with viremic blood or by crushing engorged ticks. This necessitates a radical shift in public health strategies: from simple tick-repellent education to comprehensive biological safety protocols for rural families handling large livestock.\u003c/p\u003e \u003cp\u003eBioclimatic Triggers and Spatial Clustering. The seasonality of the 24 cases (83.3% in June and July) exhibits a perfect synchrony with the phenology of the Hyalomma genus. The arid continental climate of the Turkestan region serves as a bioclimatic catalyst; rising cumulative temperatures in late spring trigger the rapid molting and questing activity of the vector.\u003c/p\u003e \u003cp\u003eThe spatial clustering in the Sauran, Shardara, and Otrar districts highlights these areas as \"ecological traps.\" In these districts, the density of cattle populations coincides with optimal tick habitats in irrigated pastoral zones. Our results align with climatic trend studies in Turkey and Iran, where warming temperatures have been linked to extended transmission seasons. This suggests that the southern regions of Kazakhstan are at the forefront of climate-driven viral expansion in Central Asia.\u003c/p\u003e \u003cp\u003eLaboratory Synergy and Molecular Sentinel Monitoring. The diagnostic success of this study (100% PCR confirmation) underscores the utility of molecular tools in early-phase detection. However, the high rate of dual positivity (PCR\u0026thinsp;+\u0026thinsp;and ELISA IgM+) in 66.7% of cases indicates that even with rapid seeking of care (2.7 days), the viral load is already at its peak upon admission. This molecular profile suggests that the CCHFV strains circulating in Turkestan are highly viremic, emphasizing the need for strict nosocomial biosafety to prevent human-to-human transmission in healthcare settings.\u003c/p\u003e \u003cp\u003eThe 2023\u0026ndash;2024 outbreaks in Turkestan demonstrate that CCHF remains an active and severe threat to public health in Kazakhstan. However, the low mortality rate is a testament to the efficacy of the regional response system. To maintain this progress, future efforts must adopt a \"One Health\" approach, integrating tick control in cattle populations with genomic surveillance of circulating strains. Turkestan serves as a global sentinel, providing vital insights into how early diagnosis can transform a traditionally fatal disease into a manageable clinical condition [\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e].\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eEthics Approval Statement This study was conducted in accordance with the Declaration of Helsinki and national ethical standards. The research protocol was reviewed and approved by the Ethics Committee of the M. Aikimbayev National Scientific Center for Especially Dangerous Infections, Kazakhstan (Approval No. __________; Date: __________). The study used anonymized retrospective surveillance data, and no personally identifiable information was included.\u003c/p\u003e\n \u003cp\u003eConsent Statement Because this research was based on retrospective analysis of fully anonymized patient data obtained through the national surveillance system, individual informed consent was not required. The requirement for informed consent was formally waived by the approving ethics committee.\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eConflict of Interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors confirm that there is no conflict of financial/nonfinancial interests related to the writing of the article.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; Contribution\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll authors participated in conceptualizing and writing the article. The final version of the manuscript was checked and approved by all authors. The authors did not receive an honorarium for the article.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis study was funded by the Committee of Science of the Ministry of Science and Higher Education of the Republic of Kazakhstan \u0026laquo;Development of new diagnostic test systems for particularly dangerous viral infections 2024-2026 (BR24992948)\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eWorld Health Organization. Crimean-Congo haemorrhagic fever: Fact sheet. 2024.\u003c/li\u003e\n \u003cli\u003eBente DA, Forrest NL, et al. CCHF: History, epidemiology and current issues. Antiviral Res. 2013;100:159-89.\u003c/li\u003e\n \u003cli\u003eShayan S, et al. Crimean-Congo Hemorrhagic Fever: A Comprehensive Review. Front Microbiol. 2022;13:100.\u003c/li\u003e\n \u003cli\u003eNurmakhanov T, et al. Natural Foci of CCHF in Kazakhstan. J Infect Dis Epidemiol. 2015;1(1).\u003c/li\u003e\n \u003cli\u003eYegemberdiyeva R, et al. Epidemiological features of CCHF in Kazakhstan. Int J Infect Dis. 2023;128:220-225.\u003c/li\u003e\n \u003cli\u003eErg\u0026ouml;n\u0026uuml;l \u0026Ouml;. Crimean-Congo hemorrhagic fever. Lancet Infect Dis. 2006;6(4):203-14.\u003c/li\u003e\n \u003cli\u003ePapa A, et al. CCHF: Genetic diversity and evolution. Antiviral Res. 2017;141:120-125.\u003c/li\u003e\n \u003cli\u003eMaltezou HC, Papa A. Risk for emergence of new endemic foci. Curr Opin Infect Dis. 2010;23:388-91.\u003c/li\u003e\n \u003cli\u003eMustafa ML, et al. CCHF in Afghanistan, 2017\u0026ndash;2024. Emerg Infect Dis. 2024;30.\u003c/li\u003e\n \u003cli\u003eSharifi-Mood B, et al. Clinical features of CCHF in Southeast Iran. J Res Med Sci. 2014;19:344-9.\u003c/li\u003e\n \u003cli\u003eTurell MJ. Role of ticks in CCHFV transmission. Springer; 2007.\u003c/li\u003e\n \u003cli\u003eAppannanavar SB, et al. CCHF: An Indian perspective. J Postgrad Med. 2013;59:223-7.\u003c/li\u003e\n \u003cli\u003eZivcec M, et al. Insights into CCHF virus pathogenesis. Virus Res. 2016;214:35-44.\u003c/li\u003e\n \u003cli\u003eAkinci E, et al. Comparison of CCHF in two different regions. J Clin Virol. 2010;49:183-6.\u003c/li\u003e\n \u003cli\u003eWhitehouse CA. CCHF virus. Antiviral Res. 2004;64:145-60.\u003c/li\u003e\n \u003cli\u003eHewson R, et al. Genome variation of CCHF virus. Virus Res. 2004;102:185-9.\u003c/li\u003e\n \u003cli\u003eOzdarendeli A, et al. Molecular epidemiology of CCHF in Turkey. J Clin Microbiol. 2010;48:2565-8.\u003c/li\u003e\n \u003cli\u003eChinikar S, et al. Seroprevalence of CCHF in Iran. Vector Borne Zoonotic Dis. 2012;12:300-4.\u003c/li\u003e\n \u003cli\u003eGencheva I, et al. CCHF in Bulgaria. Euro Surveill. 2006;11(10).\u003c/li\u003e\n \u003cli\u003eShapiyeva Z, et al. Ticks and CCHF in South Kazakhstan. Med Parasitol (Mosk). 2018.\u003c/li\u003e\n \u003cli\u003eAtshabar B, et al. Monitoring of natural foci in Turkestan. J Health Care (KZ). 2023.\u003c/li\u003e\n \u003cli\u003eSmirnova SE. Crimean-Congo hemorrhagic fever. Moscow: Medicine; 2007.\u003c/li\u003e\n \u003cli\u003eSwanepoel R, et al. CCHF in Southern Africa. Rev Infect Dis. 1987.\u003c/li\u003e\n \u003cli\u003eBurt FJ, et al. CCHF: A South African perspective. S Afr Med J. 1996.\u003c/li\u003e\n \u003cli\u003eMardani M, et al. Ribavirin in the treatment of CCHF. Clin Infect Dis. 2003.\u003c/li\u003e\n \u003cli\u003eKoksal I, et al. Clinical course of CCHF. J Clin Virol. 2007.\u003c/li\u003e\n \u003cli\u003eBakir M, et al. CCHF in children, Turkey. Emerg Infect Dis. 2005.\u003c/li\u003e\n \u003cli\u003eDeyde VM, et al. Genetic diversity of CCHFV S segment. J Virol. 2006.\u003c/li\u003e\n \u003cli\u003eRodriguez SE, et al. Molecular mechanisms of CCHFV entry. J Virol. 2018.\u003c/li\u003e\n \u003cli\u003eGarrison AR, et al. CCHF virus Gn and Gc glycoproteins. J Virol. 2013.\u003c/li\u003e\n \u003cli\u003eMorikawa S, et al. Recent trends in CCHF research. Jpn J Infect Dis. 2011.\u003c/li\u003e\n \u003cli\u003eSpengler JR, et al. CCHF virus: Progress in diagnostics. Future Virol. 2015.\u003c/li\u003e\n \u003cli\u003eDaubney R, et al. Nairobi sheep disease and CCHF relationship. J Comp Pathol. 1931.\u003c/li\u003e\n \u003cli\u003eHoogstraal H. The epidemiology of CCHF. J Med Entomol. 1979.\u003c/li\u003e\n \u003cli\u003eNational Public Health Center of Kazakhstan. Annual Epidemiological Report 2023\u0026ndash;2024. Almaty; 2024.\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"«M. Aikimbayev’s National Scientific Center of Especially Dangerous Infectious», JSC «National Holding «QazBioPharm», Almaty, Kazakhstan.","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Crimean-Congo Hemorrhagic Fever (CCHF), Descriptive Epidemiology, Kazakhstan, Turkestan Region, Hyalomma ticks, Zoonotic transmission, Case fatality rate, Public health surveillance","lastPublishedDoi":"10.21203/rs.3.rs-8410040/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8410040/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground\u003c/strong\u003e: Crimean-Congo Hemorrhagic Fever (CCHF) is a life-threatening tick-borne viral infection that poses a persistent threat to public health in Kazakhstan. This study provides an in-depth descriptive epidemiological evaluation of confirmed CCHF occurrences in the Turkestan region from May 2023 to August 2024.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods\u003c/strong\u003e: We performed a retrospective analysis of 24 laboratory-confirmed cases (RT-PCR and ELISA IgM). Data were synthesized from national surveillance reports, focusing on clinico-demographic variables and exposure pathways.\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults\u003c/strong\u003e: The case fatality rate (CFR) was remarkably low at 4.1%. Predominance was observed in males (62.5%) and rural inhabitants (91.7%). Direct interaction with cattle was the primary occupational risk factor (54.1%). Notably, a peak in June (50%) coincided with the seasonal surge of Hyalomma ticks. Clinical manifestations were dominated by severe weakness (100%) and fever (75%), while 50% of patients exhibited thrombocytopenia.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusion\u003c/strong\u003e: The paradox of high severity (54.2% severe cases) yet low mortality suggests that early clinical intervention (mean 2.7 days to admission) is a decisive factor in survival. Strategic focus must shift toward cattle-management safety and rural health literacy to mitigate spillover events.\u003c/p\u003e","manuscriptTitle":"Descriptive epidemiology of Crimean-Congo Hemorrhagic Fever Cases in the Southern Region of Kazakhstan in 2023-2024","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-01-07 08:52:39","doi":"10.21203/rs.3.rs-8410040/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"d45645aa-f72b-494c-9593-b0771bae91b2","owner":[],"postedDate":"January 7th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":60725236,"name":"Infectious Diseases"}],"tags":[],"updatedAt":"2026-01-07T08:52:39+00:00","versionOfRecord":[],"versionCreatedAt":"2026-01-07 08:52:39","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8410040","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8410040","identity":"rs-8410040","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}